Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00103 / http://dx.doi.org/10.20960/revcancer.00103

Resumen| PDF

Revisión

Avances en investigación y terapias innovadoras en cáncer de testículo

Jorge Aparicio Urtasun, Josep Esteva Gallego, Patricia Capdevila Gaudens

Prepublicado: 2025-05-14

Logo Descargas Número de descargas: 106 Logo Visitas Número de visitas: 27 Citas Citas: 0

Compártelo:

Los avances en el manejo de los tumores germinales han permitido mantener tasas de supervivencia superiores a otros tumores sólidos, pero existen áreas de investigación que potencialmente afectarán el manejo de esta enfermedad. Entre ellas, los microRNA circulantes presentan mayor sensibilidad y especificidad que AFP, BHCG y LDH. Ofrecen una amplia aplicabilidad en el diagnóstico, evaluación de respuesta, detección de enfermedad residual y diagnóstico precoz de las recidivas. La linfadenectomía retroperitoneal se está explorando activamente en el manejo del seminoma en estadio II. El estudio TIGER probablemente determine el tratamiento óptimo de segunda línea en pacientes que progresan a la quimioterapia de primera línea. El conocimiento creciente de los componentes genómicos de la resistencia a cisplatino conducirá al desarrollo de nuevas terapias para tumores recidivados y refractarios. Por último, estudios cooperativos activos permitirán un mayor conocimiento de las toxicidades a largo plazo de la quimioterapia, lo que posibilitaría una intervención precoz y reducción de estos riesgos.

Palabras Clave: Cáncer de testículo. Tumor de células germinales. Linfadenectomía retroperitoneal. Quimioterapia. microRNA. Largos supervivientes.

Descargar PDF

Bibliografía
Artículos Relacionados

Singla N, Bagrodia A, Baraban E, Frankhauser CD, Ged YMA. Testicular germ cell tumors. A review. JAMA 2025; 333: 793-803.
DOI: 10.1001/jama.2024.27122

Masterson TA, Tagawa ST. A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges. Urol Oncol 2021; 39: 561-568.
DOI: 10.1016/j.urolonc.2021.02.028

Dieckmann KP, Radtke A, Spiekermann M, et al. Serum levels of MicroRNA miR-371a-3p: A sensitive and specific new biomarker for germ cell tumours. Eur Urol 2017; 71: 213–220.
DOI: 10.1016/j.eururo.2016.07.029

Gillis AJ, Rijlaarsdam MA, Eini R, et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol Oncol 2013; 7:1083–1092.
DOI: 10.1016/j.molonc.2013.08.002

Nappi L, Thi M, Lum A, et al. Developing a highly specific biomarker for germ cell malignancies: plasma mir371 expression across the germ cell malignancy spectrum. J Clin Oncol 2019; 37: 3090–3098.
DOI: 10.1200/JCO.18.02057

Ditonno F, Franco A, Manfredi C, et al. The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives. Medicina 2023; 59: 2033.
DOI: 10.3390/medicina59112033

Almstrup K, Lobo J, Mørup N, et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol 2020; 17: 201–213.
DOI: 10.1038/s41585-020-0296-x

Lobo J, Gillis AJM, van den Berg A, et al. Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells 2019; 8: 1637.
DOI: 10.3390/cells8121637

Dieckmann K-P., Radtke A, Geczi L, et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol 2019; 37:1412–1423.
DOI: 10.1200/JCO.18.01480

Lafin JT, Singla N, Woldu SL, et al. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. Eur Urol 2020; 77: 290–292.
DOI: 10.1016/j.eururo.2019.10.005

Leão R, van Agthoven T, Figueiredo A, et al. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. J Urol. 2018; 200: 126–135.
DOI: 10.1016/j.juro.2018.02.068

Lobo J, Leão R, Gillis AJ, et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol 2021; 4: 483–491.
DOI: 10.1016/j.euo.2020.11.004

13. Bagrodia A, Savelyeva A, Lafin JT, et al. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU Int 2021; 128: 57–64.
DOI: 10.1111/bju.15288

Tarin TV, Geoffrey S, Rajesh S. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181: 627-633.
DOI: 10.1016/j.juro.2008.10.005

Wakileh GA, Ruf C, Heidenreich A, et al. Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging. World J Urol 2022; 40: 307-315.
DOI: 10.1007/s00345-021-03856-6

Joffe JK, Cafferty FH, Murphy L, et al. Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, factorial trial (TRISST). J Clin Oncol 2021; 39: 374-384.
DOI: 10.1200/JCO.2021.39.6_suppl.374

Aparicio J; On behalf of the Spanish Germ Cell Cancer Group. Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors. Clin Transl Oncol 2014; 16: 509-510.
DOI: 10.1007/s12094-014-1161-2

De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034–1039.
DOI: 10.1200/JCO.2004.07.188

Bachner M, Loriot Y, Gross-Goupil M, et al. 2-(1)(8)fluoro-deoxy-D-glucose positrón emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23: 59–64.
DOI: 10.1093/annonc/mdr052

Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354–1365.
DOI: 10.1093/jnci/dji278

Hiester A, Che Y, Lusch A, et al. Phase 2 single‐arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 2023; 84: 25‐31.
DOI: 10.1016/j.eururo.2022.10.021

Daneshmand S, Cary C, Masterson T, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol 2023; 41: 3009‐3018.
DOI: 10.1200/JCO.22.00624

Loriot Y, Texier M, Culine S, et al. The SEMITEP trial: de-escalating chemotherapy in low-volume metastatic seminoma base don early FDG-PET [abstr]. J Clin Oncol 2020; 38: 387.
DOI: 10.1200/JCO.2020.38.6_suppl.387

Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy base don tumor marker decline in por preognosis germ-cell tumours (GETG 13): a pase 3, multicentre, randomised trial. Lancet Oncol 2014; 15: 1442-1450.
DOI: 10.1016/S1470-2045(14)70490-5

Lorch A, Bascoul‐Mollevi C, Kramar A, et al. Conventional‐dose versus high‐dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178‐2184.
DOI: 10.1200/JCO.2010.32.6678

Albany C, Fazal Z, Singh R, et al. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Cancer Med 2021; 10:156–63.
DOI: 10.1002/cam4.3583

Albany C, Einhorn L, Garbo L, et al. Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: Identification and report of seven cases. Oncologist 2018; 23: 316–323.
DOI: 10.1634/theoncologist.2017-0544

Loveday C, Litchfield K, Proszek PZ, et al. Genomic landscape of platinum resistant and sensitive testicular cancers. Nat Commun 2020;11: 2189.
DOI: 10.1038/s41467-020-15768-x

Khan MR, Sheehan PK, Bazin A, et al. Late side effects of testicular cancer and treatment: a comprehensive review. Discover Oncol 2024; 15: 646.
DOI: 10.1007/s12672-024-01549-1

Groot HJ, van Leeuwen FE, Lubberts S, et al. Platinum exposure and cause‐specific mortality among patients with testicular cancer. Cancer 2020; 126: 628‐639.
DOI: 10.1002/cncr.32538

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF